Concurrent chemotherapy with intensity-modulated radiation therapy for locally advanced squamous cell carcinoma of the larynx and oropharynx: a retrospective single-institution analysis.
We present outcome data from concurrent chemotherapy and intensity-modulated radiation therapy (IMRT) for squamous cell carcinoma (SCC) of the larynx and oropharyx. Eighty patients with laryngeal (n = 15) or oropharyngeal (n = 65) SCC underwent concurrent IMRT and chemotherapy (cisplatin or carboplatin/paclitaxel). The 3-year overall survival (OS) and disease-free survival (DFS) were 81.2% and 78.3%, respectively, with a median follow-up of 31.2 months. There was a statistically significant correlation between OS and DFS with N classification (p = .0001), but not with disease site or T classification. Toxicities compared favorably with prior reports using conventional radiation therapy. This retrospective analysis reveals a very good outcome and an acceptable toxicity profile for patients with locally advanced SCC of the oropharynx and larynx treated with chemotherapy and IMRT concurrently.